CanSino Biologics Inc (hkse:06185) Share Price

Company Profile

Business description
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHN
T: +86 4009222099
https://www.cansinotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,134

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,025.40	12.80	0.14%
CAC 40	7,980.15	10.15	0.13%
DAX 40	25,858.16	181.52	-0.70%
Dow JONES (US)	52,168.09	174.47	-0.33%
FTSE 100	10,723.43	1.36	0.01%
HKSE	23,294.42	335.77	1.46%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	63,290.11	1,369.36	-2.12%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,628.52	91.87	-1.19%
S&P/ASX 200	8,908.10	16.30	0.18%
SSE Composite Index	3,599.02	52.42	-1.44%